Clinical Trial

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-08 -> 2027-08 2026-04-04
minor Completion pushed: 2026-08 -> 2027-08 2026-04-04
Trial Details
NCT Number NCT06116136
Lead Sponsor Servier Bio-Innovation LLC
Collaborators: Merck Sharp & Dohme LLC, Institut de Recherches Internationales Servier
Conditions MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Enrollment 48 participants
Start Date 2024-08-31
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-03